SLC39A2 Antibody

What is SLC39A2 and what is its primary function in cellular physiology?

SLC39A2 (also known as hZIP2) is a human zinc importer belonging to the ZIP family of transporters. This protein plays an essential role in maintaining intracellular zinc homeostasis and is typically upregulated during zinc depletion conditions . SLC39A2 facilitates the transport of zinc ions across cellular membranes, contributing to various physiological processes. Most proteins in the SLC39 family consist of eight transmembrane domains (TMDs), with extracellular or intravesicular amino and carboxy termini . SLC39A2 has been identified as a critical regulator in several tissue types, with particularly high expression observed in prostate epithelial cells where it may contribute to prostate cancer development . In cardiac tissue, Slc39a2-mediated zinc uptake has been demonstrated to modulate cardiomyocyte hypertrophy and myocardial injury responses .

What are the recommended applications for SLC39A2 antibody in research?

The SLC39A2 antibody (e.g., 21287-1-AP) has been validated for multiple experimental applications, including:

The antibody has also been validated for ELISA applications . For Western blot experiments, positive detection has been confirmed in K-562 cells . For immunohistochemistry, successful detection has been demonstrated in human colon cancer tissue and mouse brain tissue . It is important to note that antigen retrieval methods can significantly impact results, with TE buffer pH 9.0 recommended for optimal staining, though citrate buffer pH 6.0 may be used as an alternative . Researchers should titrate the antibody concentration in each testing system to obtain optimal results, as the required dilution can be sample-dependent .

What are the important storage and handling considerations for SLC39A2 antibody?

For maximum stability and activity, SLC39A2 antibody should be stored at -20°C in its provided buffer (typically PBS with 0.02% sodium azide and 50% glycerol pH 7.3) . Under these conditions, the antibody remains stable for approximately one year after shipment . It is worth noting that smaller volume sizes (e.g., 20μl) may contain 0.1% BSA as a stabilizer . Importantly, aliquoting is generally unnecessary for -20°C storage, which simplifies laboratory handling procedures . Upon receipt, researchers should minimize freeze-thaw cycles and avoid prolonged exposure to room temperature to preserve antibody functionality.

How does SLC39A2 influence zinc homeostasis in cardiac tissue and what are the implications for cardiac hypertrophy?

Research has demonstrated that zinc dyshomeostasis plays a significant role in the pathogenesis of cardiac hypertrophy, with SLC39A2 emerging as a key regulatory component . Using Zincpyr1 staining to measure intracellular zinc concentration, studies have observed a significant decrease in zinc levels during phenylephrine (PE)-induced hypertrophy of neonatal rat ventricular myocytes (NRVMs) . When screening the SLC39 family members responsible for zinc uptake, Slc39a2 was identified as the only transporter significantly altered by PE treatment .

Experimental manipulation of Slc39a2 expression has revealed its functional importance: knockdown of Slc39a2 in NRVMs reduced intracellular zinc levels and exacerbated hypertrophic responses to PE treatment . Conversely, adenovirus-mediated Slc39a2 overexpression enhanced zinc uptake and suppressed PE-induced expression of hypertrophic markers such as Nppb . As demonstrated in Figure 3 of the referenced study, Slc39a2 overexpression significantly increased zinc uptake (measured by Zinpry-1 staining) and alleviated PE-induced cardiomyocyte hypertrophy . These findings establish Slc39a2 as a crucial mediator of cardiac zinc homeostasis with direct implications for hypertrophic pathophysiology.

What signaling pathways are regulated by SLC39A2 in the context of cardiac hypertrophy?

RNA sequencing analysis of Slc39a2 knockdown in cardiomyocytes has revealed a remarkable enrichment of innate immune signaling pathways among Slc39a2-regulated genes . Principal component analysis (PCA) demonstrated that Slc39a2 deficiency establishes a unique gene expression pattern distinct from typical PE-induced hypertrophy . Following Slc39a2 knockdown, 505 genes were upregulated while 563 genes were downregulated (|log2(fold change)| ≥ 1) .

Gene Set Enrichment Analysis (GSEA) identified several key pathways affected by Slc39a2 deficiency:

• NOD-like receptor signaling pathway (significantly enriched)

• TOLL-like receptor signaling pathway (significantly enriched)

• Nuclear factor kappa B (NFκB) activation

• Interferon regulatory factors (IRFs) signaling

Western blot analysis confirmed the activation of these pathways, showing enhanced phosphorylation of P65 NFκB and signal transducer and activator of transcription 3 (STAT3) in PE-treated NRVMs . Consistent with pathway activation, the expression of inhibitor of NF-kappa B alpha (IκBα) was significantly reduced . These findings establish a mechanistic link between Slc39a2-mediated zinc homeostasis and innate immune signaling in cardiomyocyte hypertrophy.

What methodological approaches are recommended for studying SLC39A2 function in different experimental systems?

Based on successful experimental protocols reported in the literature, the following methodological approaches are recommended for investigating SLC39A2 function:

Gene Expression Analysis

For quantitative analysis of SLC39A2 expression, fluorescence quantitative PCR has been successfully employed . This approach involves:

• RNA extraction using Trizol reagent

• RNA quantification using NanoDrop

• First-strand cDNA synthesis using appropriate kits (e.g., RevertAid First Strand cDNA Synthesis Kit)

• Real-time qRT-PCR using SYBR Green PCR Master Mix and appropriate instruments (e.g., LightCyclerR 480)

• Normalization to endogenous controls such as β-actin

Protein Analysis

For protein-level studies, Western blot analysis has been effective with the following protocol:

• Cell lysis using RIPA buffer (30 min at 4°C)

• Protein quantification using BCA assay

• Fractionation on 12% SDS-PAGE gels

• Transfer to PVDF membrane (100 min at 200 mA)

• Blocking with 5% skim milk (1 hour)

• Primary antibody incubation overnight at 4°C

• HRP-conjugated secondary antibody incubation

• Detection using chemiluminescent Western detection systems

The recommended antibody dilution for Western blotting is 1:500-1:1000 .

Zinc Level Measurement

For intracellular zinc quantification, Zinpyr-1 staining has proven effective in visualizing zinc content in cardiomyocytes and other cell types . This fluorescent approach allows for both qualitative imaging and quantitative analysis of zinc levels in response to experimental manipulations of SLC39A2 expression.

How can researchers effectively modulate SLC39A2 expression for functional studies?

Several approaches have been validated for experimental manipulation of SLC39A2 expression:

• siRNA-mediated knockdown: Small interfering RNA targeting Slc39a2 has been successfully used to reduce expression levels in neonatal rat ventricular myocytes .

• Adenovirus-mediated overexpression: Recombinant adenovirus expressing Slc39a2 has been employed to increase transporter expression, with confirmed functional effects on zinc uptake and hypertrophic responses .

• Pharmacological modulation: While direct pharmacological targeting of SLC39A2 is not extensively reported, downstream pathway inhibitors such as TPCA-1 (a dual inhibitor for STAT3 and NFκB) have been used to investigate the signaling consequences of SLC39A2 modulation .

When designing knockdown or overexpression experiments, appropriate controls should include non-targeting siRNA (siNeg) or empty vector controls, respectively . Validation of expression changes should be performed at both mRNA and protein levels to confirm the efficiency of experimental manipulation.

What factors should be considered when interpreting SLC39A2 antibody results?

When working with SLC39A2 antibody, researchers should be aware of several important technical considerations:

• Molecular weight variation: While the calculated molecular weight of SLC39A2 is 33 kDa (309 amino acids), Western blot analysis has detected bands at both 33 kDa and 66-70 kDa . This discrepancy may reflect post-translational modifications, protein aggregation, or alternative isoforms.

• Antibody specificity: The SLC39A2 antibody (21287-1-AP) is a polyclonal antibody raised in rabbit using SLC39A2 fusion protein (Ag15807) as the immunogen . While it shows confirmed reactivity with human samples, cross-reactivity with other species should be validated experimentally.

• Antigen retrieval methods: For immunohistochemistry applications, the choice of antigen retrieval buffer significantly impacts staining results. TE buffer pH 9.0 is suggested as the primary method, with citrate buffer pH 6.0 as an alternative .

• Expression level variability: SLC39A2 expression is dynamically regulated by zinc availability and pathophysiological conditions. Therefore, baseline expression levels may vary considerably between cell types and experimental conditions.

How does SLC39A2 interact with IRF7 and what implications does this have for experimental design?

Research has identified a significant regulatory relationship between SLC39A2 and Interferon Regulatory Factor 7 (IRF7) . RNA-seq analysis revealed that IRF transcription factors, particularly IRF7, were enriched in Slc39a2-regulated genes . Experimental validation confirmed that IRF7 expression was significantly increased following Slc39a2 knockdown .

This interplay has important implications for experimental design:

• Researchers investigating SLC39A2 function should consider measuring IRF7 expression as a downstream readout.

• The Slc39a2/IRF7 regulatory circuit appears to contribute to alterations in innate immune signaling during cardiomyocyte hypertrophy .

• When manipulating SLC39A2 expression, potential confounding effects through IRF7-mediated pathways should be considered in experimental interpretation.

The regulatory relationship between SLC39A2 and IRF7 highlights the complex interplay between zinc homeostasis and immune signaling pathways, suggesting that zinc transporters may serve as important modulators of cellular immune responses.

What are the emerging applications for SLC39A2 antibody in disease model research?

Based on current understanding of SLC39A2 function, several promising research directions emerge:

• Cardiac disease models: Given the role of Slc39a2 in cardiac hypertrophy and myocardial injury, investigating its expression patterns in various cardiac pathologies (heart failure, ischemia-reperfusion injury, cardiomyopathies) represents an important research avenue .

• Cancer research: The high expression of SLC39A2 in prostate epithelial cells and its involvement in prostate cancer development suggest potential applications in oncology research . SLC39A2 antibody may serve as a valuable tool for studying zinc dysregulation in cancer progression.

• Immune response modulation: The newly discovered connections between SLC39A2 and innate immune signaling pathways (NOD-like receptor, TOLL-like receptor, NFκB, and IRFs) suggest potential applications in immunology research .

• Zinc deficiency models: As SLC39A2 is upregulated by zinc depletion, antibody-based detection may provide insights into cellular responses to zinc deficiency in various physiological and pathological contexts .

These emerging applications highlight the versatility of SLC39A2 antibody as a research tool across multiple disciplines, from cardiovascular biology to immunology and cancer research.